Zhangzhou Pientzehuang Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jin Ming Huang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.4yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Share Price Could Signal Some Risk
Nov 25
These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely
Nov 07Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Oct 22Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)
Sep 08Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts
Aug 20Subdued Growth No Barrier To Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price
Jul 12These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely
May 27Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price
Feb 28CEO
Jin Ming Huang (58 yo)
5.4yrs
Tenure
CN¥601,700
Compensation
Mr. Jin Ming Huang is GM & Director of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 2006. Mr. Huang served as President...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5.4yrs | CN¥601.70k | no data | |
| Chief Accountant & Director | no data | CN¥529.50k | no data | |
| Deputy GM & Director | no data | CN¥529.50k | no data | |
| Chairman of the Supervisory Committee | 2.5yrs | CN¥207.60k | no data | |
| Independent Director | 7.3yrs | CN¥80.00k | no data | |
| Director | no data | CN¥444.50k | no data | |
| Independent Director | 7.3yrs | CN¥80.00k | no data | |
| Independent Director | 6.8yrs | CN¥80.00k | no data | |
| Supervisor | 2.9yrs | no data | no data | |
| Member of the Supervisory Board | 7.3yrs | no data | no data | |
| Independent Director | 2.9yrs | CN¥80.00k | no data | |
| Employee Supervisor | 2.9yrs | no data | no data |
5.4yrs
Average Tenure
56.5yo
Average Age
Experienced Board: 600436's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:48 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhangzhou Pientzehuang Pharmaceutical., Ltd is covered by 30 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sandra Sun | BofA Global Research |
| Siti Bte Salikin | CFRA Equity Research |
| Shuchang Liu | Changjiang Securities Co. LTD. |